Literature DB >> 16908514

HIV accomplices and adversaries in macrophage infection.

Sharon M Wahl1, Teresa Greenwell-Wild, Nancy Vázquez.   

Abstract

Cell surface and intracellular proteins in macrophages influence various steps in the life cycle of lentiviruses. Characterization of these restriction and/or cofactors is essential to understanding how macrophages become unwitting HIV hosts and in fact, can coexist with a heavy viral burden. Although many of the cellular pathways co-opted by HIV in macrophages mimic those seen in CD4+ T cells, emerging evidence reveals cellular constituents of the macrophage, which may be uniquely usurped by HIV. For example, in addition to CD4 and CCR5, membrane annexin II facilitates early steps in infection of macrophages, but not in T cells. Blockade of this pathway effectively diminishes macrophage infection. Viral binding engages a macrophage-centric signaling pathway and a transcriptional profile, including genes such as p21, which benefit the virus. Once inside the cell, multiple host cell molecules are engaged to facilitate virus replication and assembly. Although the macrophage is an enabler, it also possesses innate antiviral mechanisms, including apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3) family DNA-editing enzymes to inhibit replication of HIV. Differential expression of these enzymes, which are largely neutralized by HIV to protect its rebirth, is associated with resistance or susceptibility to the virus. Higher levels of the cytidine deaminases endow potential HIV targets with a viral shield, and IFN-alpha, a natural inducer of macrophage APOBEC expression, renders macrophages tougher combatants to HIV infection. These and other manipulatable pathways may give the macrophage a fighting chance in its battle against the virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908514     DOI: 10.1189/jlb.0306130

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.

Authors:  Gang Peng; Teresa Greenwell-Wild; Salvador Nares; Wenwen Jin; Ke Jian Lei; Zoila G Rangel; Peter J Munson; Sharon M Wahl
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 2.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

3.  Systemic and mucosal differences in HIV burden, immune, and therapeutic responses.

Authors:  Sharon M Wahl; Maryann Redford; Shawna Christensen; Wendy Mack; Jon Cohn; Edward N Janoff; Jiri Mestecky; Hal B Jenson; Mahvash Navazesh; Mardge Cohen; Patricia Reichelderfer; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

Review 4.  Nature, nurture and HIV: The effect of producer cell on viral physiology.

Authors:  Sergey Iordanskiy; Steven Santos; Michael Bukrinsky
Journal:  Virology       Date:  2013-06-05       Impact factor: 3.616

Review 5.  Intestinal macrophages and response to microbial encroachment.

Authors:  P D Smith; L E Smythies; R Shen; T Greenwell-Wild; M Gliozzi; S M Wahl
Journal:  Mucosal Immunol       Date:  2010-10-20       Impact factor: 7.313

Review 6.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

7.  Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression.

Authors:  Gianni Capalbo; Thea Müller-Kuller; Ursula Dietrich; Dieter Hoelzer; Oliver G Ottmann; Urban J Scheuring
Journal:  Retrovirology       Date:  2010-03-31       Impact factor: 4.602

8.  WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection.

Authors:  R Alvarez; J Reading; D F L King; M Hayes; P Easterbrook; F Farzaneh; S Ressler; F Yang; D Rowley; A Vyakarnam
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

9.  Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon.

Authors:  Teresa Greenwell-Wild; Nancy Vázquez; Wenwen Jin; Zoila Rangel; Peter J Munson; Sharon M Wahl
Journal:  Blood       Date:  2009-06-25       Impact factor: 22.113

10.  Differential role of autophagy in CD4 T cells and macrophages during X4 and R5 HIV-1 infection.

Authors:  Lucile Espert; Mihayl Varbanov; Véronique Robert-Hebmann; Sophie Sagnier; Ian Robbins; Françoise Sanchez; Virginie Lafont; Martine Biard-Piechaczyk
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.